Diagnostic performance of four point of care cardiac troponin I assays to rule in and rule out acute myocardial infarction.

OBJECTIVE This study evaluated the diagnostic performance of four point-of-care (POC) cardiac troponin I (cTnI) assays compared to a central laboratory cTnI assay for detecting myocardial injury and diagnosing acute myocardial infarction (AMI). DESIGN AND METHODS Plasma obtained at admission, 3 h, and 6 h post-admission in 169 patients presenting with symptoms suggestive of acute coronary syndrome (ACS) was studied. cTnI concentrations were measured on the Instrumentation Laboratory prototype GEM Immuno, Radiometer AQT90, Mitsubishi PATHFAST, Abbott i-STAT and the Ortho-Clinical Diagnostic Vitros assays. MI was determined based on 99th percentiles according to Universal MI guidelines. RESULTS For ruling in MI at presentation (0 h), the GEM Immuno (sensitivity 63%, specificity 85%) and PATHFAST (sensitivity 53%, specificity 86%) were comparable to the OCD (sensitivity 68%, specificity 81%), and significantly better (p<0.05) than the AQT90 (sensitivity 26%, specificity 93%) and i-STAT (sensitivity 32%, specificity 92%). cTnI concentrations and serial rising patterns after MI differed by each assay. Negative predictive values were >90% and ROC AUCs were >0.90 after 6h for all assays. Detection of myocardial injury in non-ischemic pathologies accounted for lower than 100% specificity for MI. CONCLUSION cTnI is a sensitive biomarker for detection of myocardial injury. The analytical variability that exists between POC cTnI assays demonstrates substantial diagnostic differences for ruling in and ruling out MI in patients presenting with symptoms suggestive of ACS.

[1]  Practical implementation of the Guidelines for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction in the emergency department. , 2005, Annals of emergency medicine.

[2]  Jasbir Singh,et al.  Discordance of cardiac troponin I assays on the point-of-care i-STAT and Architect assays from Abbott Diagnostics. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[3]  J. Alpert,et al.  Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction , 2008 .

[4]  Fred S Apple,et al.  Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. , 2012, Clinical chemistry.

[5]  Brandy Drake.  A 2-h Diagnostic Protocol to Assess Patients with Chest Pain Symptoms in the Asia-Pacific region (ASPECT): A Prospective Observational Validation Study , 2011 .

[6]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[7]  P. Collinson,et al.  Analytical Characteristics of High-Sensitivity Cardiac Troponin Assays , 2014 .

[8]  P. Collinson,et al.  Very early diagnosis of chest pain by point-of-care testing: comparison of the diagnostic efficiency of a panel of cardiac biomarkers compared with troponin measurement alone in the RATPAC trial , 2011, Heart.

[9]  L. Newby,et al.  National academy of clinical biochemistry laboratory medicine practice guidelines: Point of care testing, oversight, and administration of cardiac biomarkers for acute coronary syndromes , 2007 .

[10]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[11]  Mario Plebani,et al.  Recommendations for the use of cardiac troponin measurement in acute cardiac care. , 2010, European heart journal.

[12]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[13]  D. Aronsky,et al.  Decreasing lab turnaround time improves emergency department throughput and decreases emergency medical services diversion: a simulation model. , 2008, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[14]  R. Christenson,et al.  Point: Put simply, standardization of cardiac troponin I is complicated. , 2012, Clinical chemistry.

[15]  Fred S Apple,et al.  Third universal definition of myocardial infarction , 2012 .

[16]  P. Venge,et al.  Clinical performance of a new point-of-care cardiac troponin I assay compared to three laboratory troponin assays. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[17]  B. Norrving,et al.  Global atlas on cardiovascular disease prevention and control. , 2011 .

[18]  F. Apple.  Counterpoint: Standardization of cardiac troponin I assays will not occur in my lifetime. , 2012, Clinical chemistry.

[19]  P. Kavsak,et al.  For a rapid diagnosis of acute myocardial infarction, a sensitive troponin assay is needed in the near-patient testing setting , 2012, Expert review of cardiovascular therapy.

[20]  F. Apple,et al.  Decreased patient charges following implementation of point-of-care cardiac troponin monitoring in acute coronary syndrome patients in a community hospital cardiology unit. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[21]  Deepak L. Bhatt,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.

[22]  C. Reid,et al.  2-Hour accelerated diagnostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker: the ADAPT trial. , 2012, Journal of the American College of Cardiology.

[23]  S. Normand,et al.  Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. , 2009, JAMA.